Wells Fargo initiated coverage on Revvity with a new price target
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $130.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 4/14/2026 | $95.00 | Overweight → Equal Weight | Barclays |
| 12/15/2025 | $110.00 | Buy → Neutral | BofA Securities |
| 12/9/2025 | $105.00 | Neutral | Goldman |
| 10/16/2025 | Neutral | Guggenheim | |
| 5/1/2025 | $115.00 | Neutral → Buy | UBS |
| 1/10/2025 | $130.00 | Outperform → Mkt Perform | Bernstein |
| 12/13/2024 | $138.00 | Neutral → Buy | BofA Securities |
Wolfe Research resumed coverage of Revvity with a rating of Peer Perform
Barclays downgraded Revvity from Overweight to Equal Weight and set a new price target of $95.00
BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals One platform Governed data and ontology-driven scientific context support reliable, traceable results across workflows Native agentic framework turns connected data and knowledge into task-ready insights for scientists Revvity, Inc. (NYSE:RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions
Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the
The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni
11-K - REVVITY, INC. (0000031791) (Filer)
SD - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G - REVVITY, INC. (0000031791) (Subject)
Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the
The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni
Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows